Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

BMRN BioMarin Pharmaceutical Inc

66,03

0,61 (0,93%)

29 Nov 2024 - Geschlossen

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

03/05/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Henry J. Fuchs

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more BioMarin Pharmaceutical Charts.

BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Click Here for more BioMarin Pharmaceutical Charts.

News BioMarin Pharmaceutical Inc

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
Samstag 16 November 2024 (2 Wochen vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 14 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Dienstag 12 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

BioMarin to Participate in Three Upcoming Investor Conferences
Mittwoch 6 November 2024 (3 Wochen vor) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 31 Oktober 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 29 Oktober 2024 (1 Monat vor) • Edgar (US Regulatory)

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
Dienstag 29 Oktober 2024 (1 Monat vor) • PR Newswire (US)

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
Donnerstag 24 Oktober 2024 (1 Monat vor) • GlobeNewswire Inc.

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
Mittwoch 16 Oktober 2024 (1 Monat vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 1 Oktober 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Dienstag 1 Oktober 2024 (2 Monate vor) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Montag 30 September 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere BioMarin Pharmaceutical Inc News-Artikel

JP Morgan Chase

Financial Select Sector

Deutsche Lufthansa

Invesco QQQ Trust Series 1

Deutsche Telekom

Euro vs US Dollar

Deutsche Telekom (QX)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen